NCT05945823 2025-12-29Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsTaiho Oncology, Inc.Phase 2 Active not recruiting53 enrolled
NCT05714553 2025-07-18NUC-3373 in Combination With Other Agents in Patients With Advanced Solid TumoursNuCana plcPhase 1/2 Terminated19 enrolled